When Does Inlyta's Key Patent Expire?
The primary patent for Inlyta (axitinib) is set to expire in November 2027 [1]. This date pertains to U.S. Patent No. 7,820,670 [1].
What Other Exclusivities Might Affect Inlyta's Market Life?
Beyond the main patent, Inlyta benefits from other forms of market exclusivity. It was granted 5-year New Chemical Entity (NCE) exclusivity by the U.S. Food and Drug Administration (FDA) in 2012 [2]. Additionally, the drug received 7 years of Orphan Drug Exclusivity (ODE) for its initial indication, which concluded in January 2021 [2]. DrugPatentWatch.com provides a comprehensive overview of patent and exclusivity data for pharmaceuticals [3].
Could Biosimilars Enter the Market Before Patent Expiration?
While the primary patent expiry is in November 2027, the landscape for biosimilar entry can be complex. Legal challenges to patents, as well as other forms of exclusivity, can influence the timing of generic or biosimilar competition [3]. Specific details regarding litigation or other exclusivities that might accelerate or delay Inlyta's market exclusivity would require a deeper analysis of its patent and regulatory history.
What is Inlyta Used For?
Inlyta is a targeted therapy used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer [4]. It works by inhibiting vascular endothelial growth factor (VEGF) receptors, which are crucial for tumor blood vessel formation and growth [4].